Literature DB >> 17343686

Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation.

Thomas Soliman1, Hubert Hetz, Christoph Burghuber, Georg Györi, Gerd Silberhumer, Rudolf Steininger, Ferdinand Mühlbacher, Gabriela A Berlakovich.   

Abstract

T-cell depletion is an essential aspect of clinical immunosuppression. The aim of the present study was to compare the efficacy of two dosage regimens in this setting. We retrospectively compared 246 patients (group 1) who received a 10-day antithymocyte globulin (ATG) induction protocol with 226 patients (group 2) who received a 3-day protocol. The 6-month rejection rate was 22.3% in group 1 and 12.7% in group 2 (P = 0.03). The sub-analysis showed a higher rejection rate in patients with cholestatic disease (P = 0.01), who were more numerous in group 1. This resulted in an overall difference between the groups. Rates of de novo malignancies and recurrent hepatocellular carcinoma were identical. Viral infection rates were 16% and 18%, respectively (P > 0.5). The rates of bacterial and fungal infection were also similar (37% vs. 42%, P > 0.1). However, infection and ATG administration are independent risk factors for survival. A lower rate of fatal infection was observed in group 2 (P = 0.01), while the 10-day ATG regimen had a detrimental effect on patients who had infection (P < 0.0001). Our results strongly support the application of 3-day ATG induction therapy regimen after orthotopic liver transplantation, as it is associated with the same rejection rate as long-term ATG induction therapy, without the negative survival effect of the latter due to lethal infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343686     DOI: 10.1111/j.1432-2277.2007.00463.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

1.  Use of an automated clinical management system improves outpatient immunosuppressive care following liver transplantation.

Authors:  Esther S Park; Marie R Peccoud; Kay A Wicks; Jeffrey B Halldorson; Robert L Carithers; Jorge D Reyes; James D Perkins
Journal:  J Am Med Inform Assoc       Date:  2010 Jul-Aug       Impact factor: 4.497

2.  Impact of anti-thymocyte globulin during immunosuppression induction in patients with hepatitis C after liver transplantation.

Authors:  Mauricio Garcia-Saenz-de-Sicilia; Marco A Olivera-Martinez; Wendy J Grant; David F Mercer; Chen Baojjang; Alan Langnas; Timothy McCashland
Journal:  Dig Dis Sci       Date:  2014-05-28       Impact factor: 3.199

3.  Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation.

Authors:  Timothy M Schmitt; Melissa Phillips; Robert G Sawyer; Patrick Northup; Klaus D Hagspiel; Timothy L Pruett; Hugo J R Bonatti
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

Review 4.  Review on immunosuppression in liver transplantation.

Authors:  Maryam Moini; Michael L Schilsky; Eric M Tichy
Journal:  World J Hepatol       Date:  2015-06-08

Review 5.  Liver transplantation: Current status and challenges.

Authors:  Caroline C Jadlowiec; Timucin Taner
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

6.  The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): a post-hoc between-sex analysis.

Authors:  Delia Colombo; Alessandro Zullo; Lucia Simoni; Emanuela Zagni
Journal:  BMC Nephrol       Date:  2019-12-23       Impact factor: 2.388

Review 7.  A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition.

Authors:  Markus J Barten; Uwe Schulz; Andres Beiras-Fernandez; Michael Berchtold-Herz; Udo Boeken; Jens Garbade; Stephan Hirt; Manfred Richter; Arjang Ruhpawar; Jan Dieter Schmitto; Felix Schönrath; Rene Schramm; Martin Schweiger; Markus Wilhelm; Andreas Zuckermann
Journal:  Transplant Direct       Date:  2016-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.